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Objective: Involvements of microRNA-22 (miR-22) in cancer development have attracted much attention, but its
role in tumorigenesis of gastric cancer is still largely unknown. Therefore, the aim of this study was to investigate
the expression patterns and clinical implications of miR-22 in gastric cancer.
Methods: Quantitative RT-PCR was performed to evaluate the expression levels of miR-22 in 98 pairs of gastric
cancer and normal adjacent mucosa.
Results: Compared with normal adjacent mucosa, miR-22 expression was significantly downregulated in gastric
cancer tissues (P < 0.001). Of 98 patients with gastric cancer, 58 (59.2%) were placed in the low miR-22
expression group and 40 (40.8%) were placed in the high miR-22 expression group. In addition, tumors with
low miR-22 expression had greater extent of lymph node metastasis (P = 0.02) and distant metastasis (P = 0.01),
and were at a worse stage (P = 0.01) than the tumors with high miR-22 expression. Moreover, the gastric cancer
patients with low miR-22 expression had shorter overall survival than those with high miR-22 expression
(P = 0.03). MiR-22, determined by multivariate analysis, was an independent prognostic factor for patients with
gastric cancer.
Conclusion: Our data offer the convincing evidence that the reduced expression of miR-22 was significantly
associated with malignant development of gastric cancer and may be a novel prognostic marker of this disease.
miR-22 might have potentials in the application of cancer therapy for patients with gastric cancer.
Keywords: MicroRNA-22, Gastric cancer, Prognosis, Quantitative RT-PCRIntroduction
Gastric cancer is the fourth most prevalent forms of
human cancers and the second leading cause of cancer-
related death in the world, especially in East Asian coun-
tries. Its incidence rate is 20 per 100,000 annually [1].
According to its histological subtypes, gastric cancer can
be divided into two groups: the intestinal type and the
diffuse type. The former is characterized by expansive
growth and liver metastasis; whereas the latter is charac-
terized by infiltrative growth and peritoneal dissemin-
ation [2-4]. They are both associated with Helicobacter* Correspondence: 18992891737@QQ.com
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reproduction in any medium, provided the orpylori infection that contributes to more than 80% of
cases [5]. Nowadays, gastrectomy remains the mainstay
treatment for gastric cancer, but the prognosis for ad-
vanced stage patients is still very poor. The median
survival time for patients with gastric cancer is only
6–9 months [6]. In China, the 5-year overall survival rate
of patients with gastric cancer is lower than 40%, al-
though recent advances in chemotherapy and surgical
techniques [7]. This is primarily attributed to the follo-
wing reasons: lack of diagnostic markers for early detec-
tion, weak prognostic value of histological indicators,
limited efficiency of current treatment for advanced dis-
ease and lack of molecular markers utilized for targeted
therapy [8-10]. Therefore, it is of great significance to
make a better understanding of gastric carcinogenesistd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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provement of clinical management of patients with gas-
tric cancer.
MicroRNAs (miRNAs) are a recently discovered ca-
tegory of small (19 ~ 24 nucleotides), non-protein-coding
and single-stranded endogenous RNA molecules [11].
miRNAs function as regulators of approximately 60%
protein-coding genes’ expression mainly at the post-
transcriptional level by binding to the sequences in the
3′ untranslated regions (3′-UTR) of their targeted
mRNAs resulting in translational repression or gene si-
lencing [12]. As they are involved in regulation of wide
array of biological processes including cell proliferation,
differentiation, apoptosis, metastasis, angiogenesis and
immune response, miRNAs have been considered to be
new approaches of tumor biomarkers for early cancer
diagnosis and prognosis. They may play roles in the de-
velopment and progression of cancers similar to those
played by oncogenes or tumor suppressor genes. Recent
studies have identified a number of miRNAs with aber-
rant expression in gastric cancer. For example, the com-
parison of miRNAs deregulated in gastric cancer revealed
a significant increase of several tumor-associated miRNAs
such as miR-21, -25 and -106a and miRNAs from the
miR-17-92 cluster [13]; based on the cluster analyses,
eight miRNAs (including miR-100, -143 and −145) were
upregulated specifically in diffuse-type, while four miRNA
(miR-202, -373, -494 and −498) in intestinal-type gastric
cancer [14]. In our previous study, we found that the
downregulation of miR-206 was significantly correlated
with tumor progression and may be a potent prognostic
marker of gastric cancer [15]. According to our literature
retrieval, miR-22 has been demonstrated to play important
roles in different types of cancer, such as hepatocellular
carcinoma, breast cancer, colon cancer, lung cancer, and
prostate cancer [16-22]. However, its roles in tumorige-
nesis of gastric cancer are still unknown. Because of its
involvement in several tumors in digestive system (hepato-
cellular carcinoma and colon cancer), we hypothesized
that miR-22 might play a role in gastric cancer. Thus, the
aim of the present study was to investigate the expression
patterns and clinical implications of miR-22 in gastric
cancer.
Materials and methods
Patients and tissue samples
This study was approved by the Research Ethics Commit-
tee of the 323th Hospital of PLA and Tangdu Hos-
pital of the Forth Military Medical University, China.
Written informed consent was obtained from all patients.
All specimens were handled and made anonymous ac-
cording to the ethical and legal standards.
Ninety-eight pairs of gastric cancer and matched nor-
mal adjacent mucosa were resected from gastrectomywith lymph node dissection between 1999 and 2007 at
Department of General Surgery. These patients with gas-
tric cancer included 62 males and 36 females, ranged in
age from 21 to 86 years (mean 63 years). Clinicopatho-
logic findings were based on the criteria of the tumor
node metastasis (TNM) classification of the Internatio-
nal Union against Cancer [23]. Histopathological types
of gastric cancer were classified into two types, intestinal
type and diffuse type. The intestinal type was further
classified into three differentiated types: well-differenti-
ated (tub1), moderately differentiated (tub2), and papil-
lary differentiated (pap). The diffuse type was classified
into two undifferentiated types: diffuse-adherent (por1)
and diffuse-scattered (por2). None of these patients un-
derwent endoscopic mucosal resection, palliative resec-
tion, or preoperative chemotherapy, or had synchronous
or metachronous multiple cancer in other organs. The
clinicopathologic features of these patients with gastric
cancer were summarized in Table 1.
All patients had follow-up after surgery, with X-ray
examination and tumor marker assays (carcinoembryo-
nic antigen and carbohydrate antigen 19–9) performed
every 1–3 months, computed tomography performed
every 3–6 months, and ultrasonography performed every
6 months. Median follow up period was 38 (range 6 to
139) months for all patients. Overall survival was defined
as the period between the time of surgery and death or
was censored at the last follow-up. Patients, who died of
diseases not directly related to their gastric cancers or
due to unexpected events, were excluded from this
study.
Quantitative RT-PCR
In order to detect the expression levels of miR-22 in gas-
tric cancer and matched normal adjacent mucosa, quan-
titative RT-PCR was performed. Briefly, total RNAs,
including the miRNAs, were extracted from 98 primary
gastric cancer tissues and matched normal adjacent
mucosa using the miRNeasy Mini Kit (Qiagen Inc.,
Valencia, CA, USA) according to the user’s instruc-
tion. cDNA was synthesized from 10 ng of total RNA
using TaqMan™ MicroRNA hsa-miR-22 specific primer
(Applied Biosystems) and a TaqMan™ MicroRNA Re-
verse Transcription Kit (Applied Biosystems). RNU6B was
used as an internal control. The reverse transcriptase reac-
tions contained 10 ng of total RNAs, 50 nmol/stem-loop
RT primer, 1X RT buffer, 0.25 mmol/L each of dNTP,
3.3 U/μL MultiScribe reverse transcriptase, and 0.2 U/μL
RNase inhibitor. The 15 μL reaction samples were incu-
bated in GeneAmp PCR System 9700 (Applied Bio-
systems) for 30 min at 20°C, 30 min at 42°C, 5 min at
95°C, and then held at 4°C. Quantitative real-time PCR
were performed using ABI StepOne (Applied Biosystems).
The PCR conditions were initial denaturation at 95°C for
Table 1 Correlations of miR-22 expression with the





Age (years) 98 62.8 ± 23.2 62.1 ± 23.9 NS
Gender
Male 62 (63.3) 25 (40.3) 37 (59.7) NS
Female 36 (36.7) 15 (41.7) 21 (58.3)
Histopathological type
Intestinal type
pap 5 (5.1) 2 (40.0) 3 (60.0) NS
tub1 20 (20.4) 9 (45.0) 11 (55.0)
tub2 25 (25.5) 8 (32.0) 17 (68.0)
Diffuse type
por1 15 (15.3) 6 (40.0) 9 (60.0) NS
por2 33 (33.7) 15 (45.5) 18 (54.5)
Tumor depth (pT)
pT1 40 (40.8) 20 (50.0) 20 (50.0) NS
pT2 30 (30.6) 10 (33.3) 20 (66.7)
pT3 20 (20.4) 8 (40.0) 12 (60.0)
pT4 8 (8.2) 2 (25.0) 6 (75.0)
Lymph node metastasis (pN)
pN0 50 (51.0) 27 (54.0) 23 (46.0) 0.02
pN1 20 (20.4) 8 (40.0) 12 (60.0)
pN2 15 (15.3) 4 (26.7) 11 (73.3)
pN3 13 (13.3) 1 (7.7) 12 (92.3)
Distant metastasis (pM)
pM0 86 (87.8) 39 (45.3) 47 (54.7) 0.01
pM1 12 (12.2) 1 (8.3) 11 (91.7)
pStage
I 50 (51.0) 29 (58.0) 21 (42.0) 0.02
II 15 (15.3) 5 (33.3) 10 (66.7)
III 20 (20.4) 5 (25.0) 15 (75.0)
IV 13 (13.3) 1 (7.7) 12 (92.3)
Lymphatic invasion
Negative 45 (45.9) 17 (37.8) 28 (62.2) NS
Positive 53 (54.1) 23 (43.4) 30 (56.6)
Venous invasion
Negative 68 (69.4) 23 (33.8) 45 (66.2) NS
Positive 30 (30.6) 17 (56.7) 13 (43.3)
Hematogenous recurrence
Negative 78 (79.6) 32 (41.0) 46 (59.0) NS
Positive 20 (20.4) 8 (40.0) 12 (60.0)
Note: ‘NS’ refers to ‘no significant’.
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10 sec, annealing at 56°C for 10 sec, and extension at 60°C
for 10 sec. Analysis was performed by the comparative
threshold cycle (Ct) method according to User Bulletin
no.2 (Applied Biosystems). Each sample was examined in
triplicate and the amounts of the PCR products produced
were normalized to RNU6B.
Statistical analysis
The software of SPSS version12.0 for Windows (SPSS
Inc, IL, USA) and SAS 9.1 (SAS Institute, Cary, NC) was
used for statistical analysis. Data were expressed as
means ± standard deviation (SD). The differential expres-
sion of miR-22 between gastric cancer and matched nor-
mal adjacent mucosa was evaluated by paired sample
t test. The Χ2 test was used to analyze the relationship
between miR-22 expression and the clinicopathologic
characteristics. The Kaplan–Meier method was used for
survival analysis, and differences in survival were esti-
mated using the log-rank test. Prognostic factors were
examined by univariate and multivariate analyses (Cox
proportional hazards regression model). Differences
were considered statistically significant when p was
less than 0.05.
Results
Reduced expression of microRNA-22 is associated with
advanced clinicopathologic characteristics of patients
with gastric cancer
Quantitative RT-PCR was performed to detect the differ-
ential expression of miR-22 in 98 pairs of gastric cancer
and matched normal adjacent mucosa tissues normalized
to RNU6B. As a result, miR-22 expression in gastric can-
cer was significantly lower than that in normal adjacent
mucosa (mean ± SD: 2.1 ± 1.2 vs. 3.6 ± 1.3, P < 0.001,
Figure 1).
The 98 patients with gastric cancer were classified into
two groups according to the median expression level of
miR-22 (2.2, normalized to RNU6B) as determined by
quantitative RT-PCR. Of 98 patients with gastric cancer,
58 (59.2%) were placed in the low miR-22 expression
group and 40 (40.8%) were placed in the high miR-22
expression group. The association between clinicopatho-
logic features and miR-22 expression was summarized in
Table 1. Tumors with low miR-22 expression had greater
extent of lymph node metastasis (P = 0.02) and distant
metastasis (P = 0.01), and were at a worse stage (P = 0.01)
than the tumors with high miR-22 expression.
Reduced expression of microRNA-22 confers poor
prognosis in patients with gastric cancer
All 98 patients with gastric cancer received follow-up
after surgery. No patient died of postoperative complica-
tions within 30 days at the beginning of the study period.
Figure 2 Postoperative 5-year survival curves of patients
according to the expression of miR-22. The gastric cancer
patients with low miR-22 expression had shorter overall survival than
those with high miR-22 expression (P = 0.03).
Figure 1 Expression levels of miR-22 in 98 pairs of gastric
cancer tissues and normal adjacent gastric mucosa. miR-22
expression was significantly downregulated in gastric cancer tissues
when compared with normal adjacent mucosa (P < 0.001).
Table 2 Univariate and multivariate analyses of















0.006 0.01 3.8 1.0 ~ 7.2
Lymph node metastasis (pN)
Negative/positive 0.001 0.01 4.1 1.2 ~ 8.9
Venous invasion
Negative/positive 0.03 NS 1.8 0.5 ~ 3.1
pStage
I and II and III
and IV
0.03 NS 1.2 0.09-2.3
miR-22 expression
Negative/positive 0.03 0.04 2.2 0.6 ~ 5.2
Note: ‘NS’ refers to ‘no significant’.
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high miR-22 expression was 82.5% (33/40), whereas the
rate for patients with low miR-22 expression was 58.6%
(34/58). Thus, the gastric cancer patients with low miR-
22 expression had shorter overall survival than those
with high miR-22 expression (P = 0.03, Figure 2).
The univariate and multivariate analyses were also
performed to identify factors related to patient progno-
sis. As shown in Table 2, the univariate analysis showed
that the depth of tumor invasion (P = 0.006), lymph node
metastasis (P = 0.001), venous invasion (P = 0.03), tumor
stage (P = 0.03) and miR-22 expression (P = 0.03) were
significantly related to postoperative survival. Moreover,
the multivariate regression analysis indicated that the
depth of invasion (P = 0.01), lymph node metastasis
(P = 0.01) and miR-22 expression (P = 0.04) were indepen-
dent prognostic factors for patients with gastric cancer.
Discussion
Accumulating evidences have demonstrated that miRNAs
play important roles in various physiological and patho-
logical processes, and have a robust association with car-
cinogenesis. miRNAs have been considered to be novel
biomarkers for various cancers. Among human miRNAs,
miR-22 is located at a fragile cancer-relevant genomic re-
gion in chromosome 17 (17p13.3), and is mapped to an
exon of the C17orf91 gene [24]. This miRNA plays unique
roles in specific cell types. For example, it regulates PPAR-
alpha and BMP7 signaling pathways in human chondro-
cytes [25], and the differentiation of a monocyte cell line
[26]. Recent studies have demonstrated that miR-22 is
deregulated in many types of cancers and is involved in
various cellular processes related to carcinogenesis, in-
cluding cell growth, apoptosis, motility, and cell cycle.
Zhang et al. [16] indicated that miR-22 was downregula-
ted in hepatocellular carcinoma and had considerablepotential in identification of the prognosis; Xiong et al.
[17] found that miR-22 was frequently downregulated in
ERα-positive human breast cancer cell lines and clinical
samples; Li et al. [18] identified miR-22 as a potential me-
tastasis-inhibitor in ovarian cancer; Yamakuchi et al. [19]
found that miR-22 expression in human colon cancer was
lower than in normal colon tissue, and it might have an
anti-angiogenic effect in this cancer; Ling et al. [20] ob-
served the downregulation of miR-22 in lung cancer tis-
sues and lung cancer cell lines, and also suggested that
miR-22 might exhibit excellent anti-lung cancer activity
in vitro and in vivo. All these studies suggest that miR-22
may act as a tumor suppressor. In contrast, Poliseno et al.
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human prostate cancer; Liu et al. [22] have reported that
miR-22 might act as a micro-oncogene in transformed hu-
man bronchial epithelial cells induced by anti-BPDE.
These controversial findings of miR-22 in cancer develop-
ment suggest the diverse roles of miR-22 in different types
of cancer. In the present study, we confirmed that miR-22
expression was frequently reduced in gastric cancer tissues
than in their normal adjacent mucosa. Moreover, the
downregulation of miR-22 was found to be more fre-
quently occurred in gastric cancer tissues with great ex-
tent of lymph node and distant metastases, and with an
advanced stage.
To our knowledge, the invasion and metastasis of
tumor cells are major causes of mortality in cancer pa-
tients. Therefore, the potential value of miR-22 as a
prognostic marker is of interest. Yet, there has been only
one study that has attempted to identify the prognostic
value of miR-22 for hepatocellular carcinoma. Using 160
primary hepatocellular carcinoma cases, Zhang et al.
[16] found that low miR-22 expression correlated with
poor overall survival. In line with this finding, we ana-
lyzed not only the Kaplan-Meier survival curve but also
applied Cox multivariate analysis to clarify the prognos-
tic value of miR-22 in gastric cancer. Notably, we dem-
onstrated that low miR-22 expression in gastric cancer
tissues significantly correlated with poorer overall sur-
vival. Furthermore, in Cox multivariate analysis, miR-22
expression in gastric cancer tissues showed a significant
association with overall survival.
In conclusion, our data offer the convincing evidence
that the reduced expression of miR-22 was significantly
associated with malignant development of gastric cancer
and may be a novel prognostic marker of this disease.
miR-22 might have potentials in the application of
cancer therapy for patients with gastric cancer. How-
ever, our study is limited by the number of study
cases with relatively small subgroups. Further investi-
gations with a larger number of cases would allow us
to evaluate miR-22 in a variety of clinical settings and
help us better understand its unique role in cancer
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